Vaxcyte (NASDAQ:PCVX) Stock Rating Reaffirmed by 888

888 reiterated their reiterates rating on shares of Vaxcyte (NASDAQ:PCVX – Get Rating) in a research note published on Tuesday, Benzinga reports.

PCVX has been the topic of a number of other research reports. Bank of America lifted their target price on Vaxcyte from $63.00 to $68.00 in a research report on Monday, April 17th. TD Cowen began coverage on Vaxcyte in a research report on Tuesday, April 18th. They issued an outperform rating on the stock. Needham & Company LLC reissued a buy rating and issued a $58.00 target price on shares of Vaxcyte in a research report on Tuesday, February 28th. Finally, Guggenheim dropped their target price on Vaxcyte from $66.00 to $65.00 and set a buy rating on the stock in a research report on Tuesday, February 28th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, Vaxcyte presently has an average rating of Buy and an average price target of $65.00.

Vaxcyte Price Performance

NASDAQ:PCVX opened at $53.31 on Tuesday. Vaxcyte has a fifty-two week low of $17.44 and a fifty-two week high of $54.84. The stock has a market capitalization of $4.30 billion, a PE ratio of -15.50 and a beta of 0.97. The business’s 50-day simple moving average is $40.85 and its 200-day simple moving average is $43.11.

Vaxcyte (NASDAQ:PCVX – Get Rating) last released its quarterly earnings data on Monday, February 27th. The company reported ($0.73) earnings per share for the quarter, beating the consensus estimate of ($0.84) by $0.11. On average, research analysts expect that Vaxcyte will post -3.61 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. RA Capital Management L.P. increased its position in shares of Vaxcyte by 27.9% during the 4th quarter. RA Capital Management L.P. now owns 5,857,459 shares of the company’s stock worth $280,865,000 after purchasing an additional 1,276,256 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Vaxcyte by 12.5% during the 3rd quarter. Vanguard Group Inc. now owns 4,452,145 shares of the company’s stock worth $106,851,000 after acquiring an additional 496,227 shares during the period. BlackRock Inc. boosted its stake in shares of Vaxcyte by 6.7% during the 3rd quarter. BlackRock Inc. now owns 3,492,321 shares of the company’s stock worth $83,817,000 after acquiring an additional 220,691 shares during the period. State Street Corp boosted its stake in shares of Vaxcyte by 7.4% during the 3rd quarter. State Street Corp now owns 1,993,036 shares of the company’s stock worth $47,833,000 after acquiring an additional 137,392 shares during the period. Finally, Carlyle Group Inc. bought a new position in shares of Vaxcyte during the 1st quarter worth approximately $72,080,000. Institutional investors and hedge funds own 71.50% of the company’s stock.

About Vaxcyte

(Get Rating)

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia.